Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INMB Stock Forecast 2026-2027
$2.07
Current Price
$53.70M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INMB Price Targets
+334.8%
To High Target of $9.00
+262.3%
To Median Target of $7.50
+93.2%
To Low Target of $4.00
INMB Price Momentum
+15.6%
1 Week Change
+61.7%
1 Month Change
-11.5%
1 Year Change
+32.7%
Year-to-Date Change
-36.2%
From 52W High of $3.24
+89.9%
From 52W Low of $1.09
📊 TOP ANALYST CALLS
Did INMB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inmune Bio is one of their latest high-conviction picks.
Latest INMB Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, INMB has a bullish consensus with a median price target of $7.50 (ranging from $4.00 to $9.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $2.07, the median forecast implies a 262.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Elemer Piros at LUCID CAPITAL MARKETS, projecting a 334.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INMB Analyst Ratings
4
Buy
0
Hold
0
Sell
INMB Price Target Range
Low
$4.00
Average
$7.50
High
$9.00
Current: $2.07
Latest INMB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INMB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | LUCID CAPITAL MARKETS | Elemer Piros | Buy | Upgrade | $9.00 |
| Jul 2, 2025 | Maxim Group | Buy | Maintains | $N/A | |
| Jul 1, 2025 | BTIG | Neutral | Downgrade | $N/A | |
| Jul 1, 2025 | Scotiabank | Sector Underperform | Downgrade | $N/A | |
| Feb 13, 2025 | Maxim Group | Buy | Maintains | $N/A | |
| Feb 11, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Oct 21, 2024 | Alliance Global Partners | James Molloy | Buy | Initiates | $20.00 |
| Sep 27, 2024 | Raymond James | Outperform | Initiates | $18.00 | |
| Aug 22, 2024 | Scotiabank | George Farmer | Sector Outperform | Initiates | $22.00 |
| Jun 1, 2023 | Baird | Outperform | Initiates | $N/A | |
| May 24, 2022 | BTIG | Buy | Maintains | $N/A | |
| May 24, 2022 | B. Riley Securities | Neutral | Downgrade | $N/A | |
| Jan 24, 2022 | B. Riley Securities | Buy | Maintains | $N/A | |
| Apr 21, 2021 | B. Riley FBR | Buy | Initiates | $N/A | |
| Apr 21, 2021 | B. Riley Securities | Buy | Initiates | $N/A | |
| Nov 25, 2020 | BTIG | Buy | Initiates | $N/A | |
| Nov 25, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Nov 25, 2020 | Roth Capital | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Maxim Group | Buy | Initiates | $N/A |
Inmune Bio Inc. (INMB) Competitors
The following stocks are similar to Inmune Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inmune Bio Inc. (INMB) Financial Data
Inmune Bio Inc. has a market capitalization of $53.70M with a P/E ratio of -1.1x. The company generates $50,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -61,738.0% and return on equity of -168.8%.
Valuation Metrics
Market Cap
$53.70M
Enterprise Value
$29.60M
P/E Ratio
-1.1x
PEG Ratio
0.0x
Price/Sales
1,074.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-61,738.0%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+38.8%
Current Ratio
4.2x
Debt/Equity
7.7x
ROE
-168.8%
ROA
-52.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inmune Bio Inc. (INMB) Business Model
About Inmune Bio Inc.
What They Do
Develops innovative therapies for immune system modulation.
Business Model
The company focuses on research and development of therapies aimed at managing and curing conditions by targeting the innate immune system. It generates revenue through partnerships with research institutions and by developing proprietary technologies that lead to advanced therapeutic solutions.
Additional Information
Inmune Bio Inc. operates in the biotechnology sector, specifically addressing autoimmune diseases, cancer, and neurodegenerative disorders. Its approach leverages the body's natural defense mechanisms to create effective treatments with minimized side effects, positioning the company as a leader in immune-based therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Mr. David J. Moss M.B.A.
Country
United States
IPO Year
N/A
Website
www.inmunebio.comInmune Bio Inc. (INMB) Latest News & Analysis
Latest News
Quick Summary
A study indicates that XPro1595 can neutralize soluble TNF, preventing amyloid pathology rise after head injuries and improving cognitive and pain outcomes, potentially impacting Alzheimer's treatment.
Why It Matters
The findings suggest potential for XPro1595 as a treatment for Alzheimer's linked to head injuries, impacting pharmaceutical investment and development in neurodegenerative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
7 days ago
Quick Summary
Advanced MRI analyses at Week 24 indicate early changes in white matter myelin integrity and cortical microstructure, suggesting biologic activity from selective soluble TNF inhibition.
Why It Matters
The early treatment-related changes in brain structure indicate potential efficacy of the therapy, which can influence stock prices and investment decisions in biotech firms involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A global framework has been secured for composition-of-matter and method-of-treatment claims for Ebstrocel, targeting Epidermolysis Bullosa, extending protection until 2045.
Why It Matters
Securing a global framework for Ebstrocel's claims enhances market exclusivity, potentially increasing revenue streams and investor confidence in future growth and innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
INmune Bio Inc. received positive feedback from the MHRA on its CORDStrom™ (Ebstrocel™) for RDEB, confirming alignment on regulatory questions, supporting its 2026 Marketing Authorization Application.
Why It Matters
Successful regulatory feedback enhances INmune Bio's path to marketing authorization for Ebstrocel™, potentially boosting its market value and investor confidence in the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CORDStrom™ has received approval for its pediatric strategy in the UK, validating its clinical data and expediting the regulatory process.
Why It Matters
Approval of the pediatric strategy boosts CORDStrom™’s market potential and speeds up its regulatory process, indicating strong future revenue opportunities for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
XPro1595 demonstrated a significant treatment effect in the full mITT population (p=0.0028) with broad tissue-level engagement, based on a study of 200 participants.
Why It Matters
XPro1595's strong treatment effect indicates potential for market approval and revenue growth, making it a key asset for investors in biotech and pharma sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INMB Stock
What is Inmune Bio Inc.'s (INMB) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Inmune Bio Inc. (INMB) has a median price target of $7.50. The highest price target is $9.00 and the lowest is $4.00.
Is INMB stock a good investment in 2027?
According to current analyst ratings, INMB has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INMB stock?
Wall Street analysts predict INMB stock could reach $7.50 in the next 12 months. This represents a 262.3% increase from the current price of $2.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inmune Bio Inc.'s business model?
The company focuses on research and development of therapies aimed at managing and curing conditions by targeting the innate immune system. It generates revenue through partnerships with research institutions and by developing proprietary technologies that lead to advanced therapeutic solutions.
What is the highest forecasted price for INMB Inmune Bio Inc.?
The highest price target for INMB is $9.00 from Elemer Piros at LUCID CAPITAL MARKETS, which represents a 334.8% increase from the current price of $2.07.
What is the lowest forecasted price for INMB Inmune Bio Inc.?
The lowest price target for INMB is $4.00 from at , which represents a 93.2% increase from the current price of $2.07.
What is the overall INMB consensus from analysts for Inmune Bio Inc.?
The overall analyst consensus for INMB is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are INMB stock price projections?
Stock price projections, including those for Inmune Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 8:06 AM UTC